Russell Katz

4.3k total citations · 2 hit papers
24 papers, 1.9k citations indexed

About

Russell Katz is a scholar working on Economics and Econometrics, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Russell Katz has authored 24 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 5 papers in Physiology and 5 papers in Psychiatry and Mental health. Recurrent topics in Russell Katz's work include Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (8 papers) and Statistical Methods in Clinical Trials (5 papers). Russell Katz is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (13 papers), Pharmaceutical Economics and Policy (8 papers) and Statistical Methods in Clinical Trials (5 papers). Russell Katz collaborates with scholars based in United States, United Kingdom and Belgium. Russell Katz's co-authors include Nicholas Kozauer, Brian G. Rohrback, Benjamin J. Whalley, José Martínez‐Orgado, J. Helen Cross, Daniel Friedman, Jacqueline A. French, Orrin Devinsky, Didier Jutras‐Aswad and Javier Fernández‐Ruíz and has published in prestigious journals such as New England Journal of Medicine, Nature Reviews Drug Discovery and The Journals of Gerontology Series A.

In The Last Decade

Russell Katz

24 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders

2014 690 citations Russell Katz et al. Epilepsia profile →
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

2010 469 citations Harald Hampel, Richard Frank et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Russell Katz United States	13	721	566	514	395	293	24	1.9k
Richard D. Hartman United States	25	563 0.8×	544 1.0×	427 0.8×	257 0.7×	276 0.9×	62	1.9k
Hans Jörg Möbius Germany	16	863 1.2×	911 1.6×	934 1.8×	618 1.6×	452 1.5×	22	2.7k
Shinji Matsunaga Japan	26	429 0.6×	561 1.0×	472 0.9×	248 0.6×	411 1.4×	70	2.0k
Celedon Gonzales United States	19	707 1.0×	351 0.6×	907 1.8×	287 0.7×	372 1.3×	31	1.7k
Scott W. Andersen United States	21	812 1.1×	1.8k 3.1×	1.1k 2.2×	251 0.6×	348 1.2×	65	3.0k
Carlos Perdomo United States	29	970 1.3×	1.6k 2.8×	587 1.1×	319 0.8×	305 1.0×	87	3.3k
Rachel Schindler United States	21	362 0.5×	808 1.4×	932 1.8×	144 0.4×	269 0.9×	49	2.2k
James Kost United States	19	369 0.5×	811 1.4×	1.0k 2.0×	226 0.6×	322 1.1×	34	2.5k
Sharon L. Rogers United States	6	679 0.9×	709 1.3×	376 0.7×	107 0.3×	213 0.7×	8	1.5k
Alette M. Wessels United States	19	319 0.4×	708 1.3×	1.0k 2.0×	139 0.4×	269 0.9×	49	1.9k

Countries citing papers authored by Russell Katz

Since Specialization

Citations

This map shows the geographic impact of Russell Katz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell Katz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell Katz more than expected).

Fields of papers citing papers by Russell Katz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell Katz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell Katz. The network helps show where Russell Katz may publish in the future.

Co-authorship network of co-authors of Russell Katz

This figure shows the co-authorship network connecting the top 25 collaborators of Russell Katz. A scholar is included among the top collaborators of Russell Katz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell Katz. Russell Katz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Katz, Russell, et al.. (2021). Development and Application of a Liquid Chromatography-Mass Spectrometry Method for Residual Iodixanol Quantification in AAV-Based Gene Therapy Product Development. Human Gene Therapy. 33(1-2). 103–108. 5 indexed citations

Kieburtz, Karl, Russell Katz, Andrew McGarry, & C. Warren Olanow. (2020). A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another Pandemic. Movement Disorders. 36(1). 59–63. 15 indexed citations

Olanow, C. Warren, Karl Kieburtz, & Russell Katz. (2017). Clinical approaches to the development of a neuroprotective therapy for PD. Experimental Neurology. 298(Pt B). 246–251. 26 indexed citations

Kieburtz, Karl, Russell Katz, & C. Warren Olanow. (2017). New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States. Movement Disorders. 33(6). 920–927. 9 indexed citations

Hendrix, James A., Randall J. Bateman, H. Robert Brashear, et al.. (2016). Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. Alzheimer s & Dementia. 12(5). 623–630. 38 indexed citations

Vellas, Bruno, Randall J. Bateman, Kaj Blennow, et al.. (2015). ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE. The Journal of Prevention of Alzheimer s Disease. 2(2). 1–8. 32 indexed citations

Stephenson, Diane, Lisa J. Bain, Donald A. Berry, et al.. (2014). Charting a path toward combination therapy for Alzheimer’s disease. Expert Review of Neurotherapeutics. 15(1). 107–113. 31 indexed citations

Kozauer, Nicholas & Russell Katz. (2013). Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease. New England Journal of Medicine. 368(13). 1169–1171. 144 indexed citations

Reiman, Eric M., Roberta Dı́az Brinton, Russell Katz, et al.. (2012). Considerations in the Design of Clinical Trials for Cognitive Aging. The Journals of Gerontology Series A. 67(7). 766–772. 10 indexed citations

10.

Katz, Russell. (2011). Why are epilepsy trials failing? Interview with Russell Katz. Clinical Investigation. 1(11). 1487–1489. 1 indexed citations

11.

Hampel, Harald, Richard Frank, Karl Broich, et al.. (2010). Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Reviews Drug Discovery. 9(7). 560–574. 469 indexed citations breakdown →

12.

Katz, Russell. (2008). Food and Drug Administration Regulation. CNS Spectrums. 13(S16). 45–46. 3 indexed citations

13.

Katz, Russell. (2004). Biomarkers and surrogate markers: An FDA perspective. PubMed. 1(2). 189–195. 243 indexed citations

14.

Katz, Russell. (2004). FDA: Evidentiary standards for drug development and approval. PubMed. 1(3). 307–316. 65 indexed citations

15.

Katz, Russell. (2004). Biomarkers and surrogate markers: An FDA perspective. Neurotherapeutics. 1(2). 189–195. 15 indexed citations

16.

Katz, Russell. (2003). Issues in Clinical Trial Design from the FDA Perspective. Epilepsia. 44(s7). 9–15. 4 indexed citations

17.

Katz, Russell, et al.. (2003). Regulatory Aspects of Vascular Dementia in the United States. International Psychogeriatrics. 15. 293–295. 12 indexed citations

18.

Katz, Russell, et al.. (2001). The Use of Imaging as Biomarkers in Drug Development: Regulatory Issues Worldwide. The Journal of Clinical Pharmacology. 41(S7). 118S–118S. 2 indexed citations

19.

Dysken, Maurice W., Russell Katz, Frank Stallone, & Michael A. Kuskowski. (1989). Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia. Journal of Neuropsychiatry. 1(3). 249–252. 8 indexed citations

20.

Katz, Russell & Michael L. Tushman. (1987). An Investigation into the Managerial Roles and Career Paths of Gatekeepers and Project Supervisors in a Major R&D Facility : R&D Management. 2(4). 518–519. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact